Oncolytics Biotech (ONCY) Notes Payables (2019 - 2025)

Oncolytics Biotech (ONCY) has 7 years of Notes Payables data on file, last reported at $77000.0 in Q4 2025.

• On a quarterly basis, Notes Payables fell 89.02% year-over-year to $77000.0 in Q4 2025; TTM through Dec 2025 was $77000.0, a 89.02% decrease from a year earlier, with the FY2025 full-year figure at $77000.0, down 66.52% from the prior year.
• Notes Payables for Q4 2025 stood at $77000.0, up from $21072.4 in the prior quarter.
• Over the last five years, Notes Payables for ONCY reached as high as $3.9 million in Q3 2023 and fell as low as $21072.4 in Q3 2025.
• Historically, Notes Payables has averaged $453101.1 across 5 years, with a median of $119579.2 in 2021.
• Across the five-year window, Notes Payables jumped 10007.7% in 2023 and slumped 97.37% in 2025, its largest moves.
• Year by year, Notes Payables stood at $44426.8 in 2021, then jumped by 31.0% to $58199.5 in 2022, then surged by 152.42% to $146907.1 in 2023, then soared by 377.53% to $701532.2 in 2024, then plunged by 89.02% to $77000.0 in 2025.
• Per Business Quant data, the three most recent Notes Payables figures were $77000.0 in Q4 2025, $21072.4 in Q3 2025, and $739033.6 in Q2 2025.